Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-01
2005-02-01
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S131000
Reexamination Certificate
active
06849650
ABSTRACT:
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
REFERENCES:
patent: 6191166 (2001-02-01), Audia
patent: 6262302 (2001-07-01), Wu et al.
patent: 0 647 632 (1995-04-01), None
patent: 0 652 009 (1995-05-01), None
patent: 0 732 399 (1995-09-01), None
patent: 0 778 266 (1997-06-01), None
patent: 9400438 (1994-01-01), None
patent: 9509838 (1995-04-01), None
patent: 9622997 (1996-08-01), None
patent: 9639194 (1996-12-01), None
Adkins, H., et al. “The synthesis of N-(2-benzyl-4-delta 2-oxazolinoyl)-valine”,Journal of the American Chemical Society, 76(1):147-52 (1954).
Adams, et al., “Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids”, Bioorganic & Medicinal Chemistry Letters 8 :333-338 (1998).
Cordell, Barbara, “β-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease”, Annu. Rev. Pharmacol. Toxicol. 34: 69-89 (1994).
Gilbert, I., et al. “Amide bond replacement: incorporation of a 2,5,5-trisubstituted imidiazoline into dipeptides and into a CCK-4 derivative.”Tetrahedron Letters. 32 (20):2277-80 (1991).
Wipf, P., et al. “Synthesis of peptide thiazolines from beta-hydroxythioamides. An investigation of racemization in cyclodehydration protocols”,Tetrahedron Letters. 35 (30):5397-400 (1994).
Hirotsu, Y., et al. “Synthetic studies on bacitracin. VII. Isomerization of amino acid components of thiazoline peptides.”Bulletin of the Chemical Society of Japan43 (6):1870-1873 (1970).
Smith, et al., “β-APP Processing as a Therapeutic Target for Alzheimer's Disease”, Current Pharmaceutical Design, 3(4): 439-445 (1997).
Yonetani, K., et al. “Racemization of amino acid residues fused in thiazoline, oxazoline, and imidazoline rings.”Bulletin of the Chemical Society of Japan. 46 (11):2203-2205 (1975).
Audia James E.
Droste James
Latimer Lee H.
Nissen Jeffrey S.
Porter Warren J.
Athena Neurosciences, Inc.
Burns Doane , Swecker, Mathis LLP
Eli Lilly & Company
Lambkin Deborah C.
LandOfFree
Heterocyclic compounds, pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds, pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497011